ASCO 2026 Top 10 trials to watch
Chicago, May 29–June 2, 2026
Past congress.
Top 10 trials to watch
The breast cancer trials Dr. Gil Morgan picked to watch in Chicago, each led by its abstract number. The congress’s coverage is not on the site yet.
- Abstract 500OPTIMATest-directed chemotherapy in high clinical risk ER+ HER2− early breast cancer (phase III)
- Abstract LBA1006PERSEVERA BCGiredestrant + palbociclib vs letrozole + palbociclib as 1L therapy in ER+ HER2− LA/MBC (phase III)
- Abstract 507KEYNOTE-522Neoadjuvant pembrolizumab + chemo → adjuvant pembrolizumab for high-risk early TNBC: final analysis
- Abstract LBA1007SERENA-61L camizestrant for emergent ESR1 mutations in advanced breast cancer: final PFS2 (phase III)
- Abstract 502LIDERA BCGiredestrant in ER+ HER2− early breast cancer: efficacy/safety by menopausal status (phase III)
- Abstract LBA1000ASCENT-04Sacituzumab govitecan + pembrolizumab vs chemo + pembrolizumab in 1L PD-L1+ mTNBC: PFS2
- Abstract 501NATALEEPrognostic and predictive impact of baseline gene expression (EXP) in the NATALEE trial of adjuvant (ADJ) ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in HR+/HER2− early breast cancer (EBC)
- Abstract LBA503SENOMACOmission of axillary dissection in breast cancer with sentinel LN macrometastases: OS and arm morbidity
- Abstract 1001ASCENT-03Sacituzumab govitecan vs chemotherapy in 1L mTNBC: PFS2 and subsequent therapies
- Abstract LBA1003Izalontamab brengitecan vs physician’s choice chemotherapy in unresectable LA/metastatic TNBC (phase III)